NIH Weekly Funding Opportunities and Policy Notices
Notice NOT-HD-18-011 from the NIH Guide for Grants and Contracts
Notice NOT-FD-18-011 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-773 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages collaborative research applications on drug abuse and addiction that: 1. Take advantage of unusual opportunities that exist outside the United States to access talent, resources, populations, or environmental conditions in other countries that will speed scientific discovery 2. Describe how the research will significantly advance U.S. health sciences 3. Demonstrate specific relevance to the NIDA mission and objectives. To determine whether your research plan is relevant to the NIDA mission and objectives, review the NIDA Strategic Plan (https://www.drugabuse.gov/about-nida/2016-2020-nida-strategic-plan). Where feasible, applications should address NIDAs international scientific priority areas (https://www.drugabuse.gov/international/research-priorities) 4. Include an investigator from a U.S. institution and a non-U.S. citizen partner living and working in another country.
Funding Opportunity PAR-18-777 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks grant applications to develop major advances in genomic technologies. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained genomics technology throughput increases, cost decreases, and improvements in ease of use. The proposed technology development work should allow comprehensive genomic analysis of features not assayable today, or an increase of no less than an order of magnitude improvement in an existing technology in terms of data quality, throughput, efficiency or comprehensiveness (individually or in combination). This FOA explicitly excludes the development of novel technologies for DNA sequencing and for direct RNA sequencing; those projects should respond to a parallel set of FOAs (RFA-HG-18-001, RFA-HG-18-002, and RFA-HG-18-003).
Funding Opportunity PAR-18-779 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages SBIR grant applications from small businesses to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next three to five years.
Funding Opportunity PAR-18-778 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) seeks grant applications to develop major advances in genomic technologies. Advances in genomics and more broadly in biomedical research have been greatly facilitated by significant and sustained genomics technology throughput increases, cost decreases, and improvements in ease of use. The proposed technology development work should allow comprehensive genomic analysis of features not assayable today, or an increase of no less than an order of magnitude improvement in an existing technology in terms of data quality, throughput, efficiency or comprehensiveness (individually or in combination). This FOA explicitly excludes the development of novel technologies for DNA sequencing and for direct RNA sequencing; those projects should respond to a parallel set of FOAs (RFA-HG-18-001, RFA-HG-18-002, and RFA-HG-18-003).
Funding Opportunity PA-18-776 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages applications to improve health outcomes for women, infants and children, by stimulating interdisciplinary research focused on maternal nutrition and pre-pregnancy obesity. Maternal health significantly impacts not only the mother but also the intrauterine environment, and subsequently fetal development and the health of the newborn.
Funding Opportunity PA-18-775 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) for R34 applications seeks to support: (a) pilot and/or feasibility testing of innovative new, revised, or adapted prevention intervention approaches to prevent or delay the initiation and onset of drug and alcohol use, the progression to misuse or problem use or alcohol and other substance use disorder, reduce drinking and driving and deaths related to impaired driving, and the drug- or alcohol-related acquisition or transmission of HIV infection and viral hepatitis among diverse populations and settings; and, (b) pre-trial feasibility and acceptability testing for prevention services and systems research. It is expected that research conducted via this R34 mechanism will consist of studies that are a pre-requisite for preparing and submitting subsequent applications for larger scale drug or alcohol abuse prevention and/or drug- or alcohol-related HIV prevention intervention studies. This R34 FOA does not support applications for which the sole focus is development of intervention protocols, manuals, or the standardization of protocols. Any intervention development work must be imbedded within a pilot/feasibility study. Of particular interest is prevention research that addresses current public health priorities and priority settings and systems.
Notice NOT-TR-18-025 from the NIH Guide for Grants and Contracts
Notice NOT-NR-18-010 from the NIH Guide for Grants and Contracts
Funding Opportunity PA-18-774 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) encourages pilot and preliminary research in preparation for larger-scale services research effectiveness trials. Relevant trials may test a wide range of approaches, including interventions, practices, and policies designed to optimize access to, and the quality, effectiveness, affordability and utilization of drug, tobacco, or alcohol use disorder treatments and related services, as well as services for comorbid medical and mental disorder conditions. Relevant approaches may include both those that are novel, and those that are commonly used in practice but lack an evidence base. This FOA provides resources for assessing the feasibility, acceptability, and utility of these approaches, in addition to usual trial preparation activities.
Notice NOT-DA-18-013 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-DK-18-002 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) invites applications for studies to understand the effects of type 1 diabetes (T1D) on bone mass and quality and/or fracture risk. Researchers may propose investigations in newly recruited subjects or using subjects and/or samples from ongoing clinical studies of individuals with for T1D.
Funding Opportunity PA-18-770 from the NIH Guide for Grants and Contracts. These administrative supplements provide funds to awarded P30 Environmental Health Sciences Core Centers to enhance interactions across Centers to address emerging issues and to advance research, translational research, and community engagement.
Funding Opportunity PAR-18-769 from the NIH Guide for Grants and Contracts. The purpose of the R01 grant program is to develop an understanding of the risks and conditions associated with occupational diseases and injuries, to explore methods for reducing risks and preventing or minimizing exposure to hazardous conditions in the workplace, and to translate significant scientific findings into prevention practices and products that will effectively reduce work-related illnesses and injuries. Applicants must concisely describe the occupational health burden(s) being addressed in their proposal while also linking the need for the proposed research activities to planned outputs that will help address or alleviate this burden. Applicants should clearly articulate the anticipated impacts of the proposed research, both during the project period and beyond.
Funding Opportunity RFA-MH-19-136 from the NIH Guide for Grants and Contracts. The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.
Notice NOT-DA-18-011 from the NIH Guide for Grants and Contracts
Funding Opportunity RFA-HL-19-027 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide support for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute (NHLBI) and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. The FOA will support the development of feasible and well-designed clinical trials utilizing consultative services provided by the Innovative Clinical Trials Resource (ICTR) (N01).
Funding Opportunity PAR-18-768 from the NIH Guide for Grants and Contracts. The purpose of this FOA is to provide access to a consultative resource for planning activities for late phase (phase II and beyond) single-site or multi-site investigator-initiated clinical trials that address critical clinical questions within the mission of the National Heart, Lung, and Blood Institute (NHLBI) and that require non-traditional clinical trial designs with the opportunity for statistical novelty and/or innovation. The FOA will support the development of feasible and well-designed clinical trials utilizing consultative services provided by the Innovative Clinical Trials Resource (ICTR) (N01).
Notice NOT-EB-18-013 from the NIH Guide for Grants and Contracts